Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
50%(1 trials)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_2
3
60%
Ph phase_4
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 41 (20.0%)

Trials by Status

completed240%
not_yet_recruiting120%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_2

EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL.

NCT07543640
completedphase_2

Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH

NCT06677788
recruitingearly_phase_1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT06643221
recruitingphase_4

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

NCT05682859
completedphase_2

Trial of Roflumilast in Asthma Management (TRIM)

NCT03532490

Clinical Trials (5)

Showing 5 of 5 trials
NCT07543640Phase 2

EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL.

Not Yet Recruiting
NCT06677788Phase 2

Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH

Completed
NCT06643221Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Recruiting
NCT05682859Phase 4

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

Recruiting
NCT03532490Phase 2

Trial of Roflumilast in Asthma Management (TRIM)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5